Source:http://linkedlifedata.com/resource/pubmed/id/13130315
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2003-9-17
|
| pubmed:abstractText |
One limitation of ASCT is the potential reinfusion of tumor cells contaminating PBSC. The Eligix B cell SC system consists of high-density microparticles coated with anti-B cell antibodies. To determine if this system eliminates B cells and lymphoma cells from PBSC, immunocytochemistry and PCR of the bcl-2/IgH rearrangement were performed, and correlated with patient outcome after ASCT. Eligible patients (n=29) had relapsed or transformed follicular NHL with bone marrow involvement <20%, and all lymph nodes <5 cm. PBSCs were mobilized with cyclophosphamide/G-CSF (n=21), and patients were conditioned with cyclophosphamide, carmustine and etoposide. Using immunocytochemistry on PBSC, the median number of CD20+ cells pre-purge was 310/10(6) (range 0-16692) and post-purge was 0.75/10(6); the median log B cell depletion was 2.7 (range 1.4-3.9). B cell depletion correlated with PFS after ASCT (P=0.06). Of 17 available samples for PCR, only four had a detectable t(14;18) breakpoint. After purging, all four remained PCR+; two had a 1-3 log depletion of lymphoma cells. At median follow-up of 18 months, 10 patients, including five infused with PCR-negative PBSC, have had disease progression. The paucity of PCR-informative patients, possibly related to in vivo rituximab therapy, limited the utility of minimal residual disease as a surrogate marker of clinical outcome.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
32
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
681-6
|
| pubmed:dateRevised |
2009-11-3
|
| pubmed:meshHeading |
pubmed-meshheading:13130315-Adult,
pubmed-meshheading:13130315-Aged,
pubmed-meshheading:13130315-Antigens, CD20,
pubmed-meshheading:13130315-B-Lymphocytes,
pubmed-meshheading:13130315-Blood Component Removal,
pubmed-meshheading:13130315-Cell Separation,
pubmed-meshheading:13130315-Disease Progression,
pubmed-meshheading:13130315-Female,
pubmed-meshheading:13130315-Graft Survival,
pubmed-meshheading:13130315-Humans,
pubmed-meshheading:13130315-Lymphocyte Depletion,
pubmed-meshheading:13130315-Lymphoma, Follicular,
pubmed-meshheading:13130315-Male,
pubmed-meshheading:13130315-Middle Aged,
pubmed-meshheading:13130315-Neoplastic Cells, Circulating,
pubmed-meshheading:13130315-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:13130315-Survival Analysis,
pubmed-meshheading:13130315-Transplantation, Autologous,
pubmed-meshheading:13130315-Treatment Outcome
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma.
|
| pubmed:affiliation |
Lymphoma Program, James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA. Jonathan_friedberg@urmc.rochester.edu
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|